22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

In Memory of Denis Lucquin

Biotalys achieves first milestone in bioinsecticide partnership with Syngenta

Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth